Skip to Content
Merck
  • Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.

Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.

Journal of pharmacological sciences (2007-03-08)
Takahiro Matsuya, Kazuhiro Takuma, Kosuke Sato, Makoto Asai, Yoshihiro Murakami, Sosuke Miyoshi, Akihiro Noda, Taku Nagai, Hiroyuki Mizoguchi, Shintaro Nishimura, Kiyofumi Yamada
ABSTRACT

In this study, we examined the combination effects of L-DOPA and adenosine receptor antagonists on rotational behaviors in a hemi-Parkinsonian mouse model induced by unilateral 6-hydroxydopamine (6-OHDA) injection. The adenosine A(2A) antagonist SCH-58261, but not the A(1)-receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine or A(2B)-receptor antagonist alloxazine, synergistically potentiated the L-DOPA-induced rotational behaviors in the 6-OHDA-lesioned mice. In addtion, the 6-OHDA-induced lesions of the dopaminergic system did not affect the in vivo binding of an adenosine A(2A)-receptor tracer [(11)C]SCH-442416 in the striatatum. These findings suggest that adenosine A(2A) antagonists are extremely useful for pharmacotherapy of L-DOPA in Parkinson's disease patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
SCH-442416, ≥98% (HPLC)